Please login to the form below

Not currently logged in
Email:
Password:

Biogen-Samsung

This page shows the latest Biogen-Samsung news and features for those working in and with pharma, biotech and healthcare.

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Settlement clears path for Biogen, Samsung’ s Humira biosimilar. Agreement could see Europe access Imraldi as early as October this year. ... Biogen and partner Samsung Bioepis have agreed a deal that will allow their biosimilar version of AbbVie’s

Latest news

  • First Herceptin biosimilar cleared in Europe First Herceptin biosimilar cleared in Europe

    Samsung Bioepis has claimed the distinction of getting the first biosimilar of Roche’s $6.8bn breast cancer blockbuster Herceptin in the EU. ... The South Korea-based joint venture between Samsung and Biogen says the new biosimilar, called Ontruzant,

  • Samsung deal with Takeda looks beyond biosimilars Samsung deal with Takeda looks beyond biosimilars

    Samsung deal with Takeda looks beyond biosimilars. The duo plan to develop “multiple novel biologic therapies”. ... hoped. For Samsung Bioepis - a joint venture between Samsung and Biogen set up five years ago - the deal takes it from the relatively

  • Biogen launches Remicade biosimilar in the UK Biogen launches Remicade biosimilar in the UK

    Biogen launches Remicade biosimilar in the UK. Flixabi provides another low-cost alternative to J&J’ s biggest-selling drug. ... Developed by Samsung Bioepis - a joint venture between Biogen and Samsung BioLogics - and marketed in the EU by Biogen,

  • Novartis gets FDA panel backing for biosimilar Enbrel Novartis gets FDA panel backing for biosimilar Enbrel

    Samsung Bioepis - a joint venture between South Korea's Samsung and Biogen - bagged EU approval for their Benepali biosimilar in January and has already launched it in several markets, while GP2015

  • Second Remicade biosimilar given green light in Europe Second Remicade biosimilar given green light in Europe

    Second Remicade biosimilar given green light in Europe. Samsung Bioepis’ Flixabi provides another lower-cost treatment option. ... year. It has been developed by Samsung Bioepis - a joint venture between Samsung BioLogics and Biogen - and will be sold

More from news
Approximately 3 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    S Korea. Preclinical as of Dec 2012. Rituxan/Mabthera (Rituximab). SAIT101. Samsung Bioepis. ... This is because only larger entities like Samsung Bioepis and Hanwha Chemical have sufficient resources to absorb the financial risks of failed trials.

  • Pharma deals during February 2013 Pharma deals during February 2013

    This time Merck is not going it alone, but has announced a collaboration with Samsung Bioepis (the joint venture between Samsung and Biogen Idec set up in December 2011. ... Samsung Bioepis will be responsible for all the development work, whilst Merck

  • Pharma deals during July 2012 Pharma deals during July 2012

    Two weeks prior to the announcement of the collaboration between Amgen and Watson, Biogen Idec and Samsung Biologics announced the establishment of a $300m joint venture to develop and commercialise biosimilars. ... With these developments, there is the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics